In contrast to the traditional mechanism of drug action that relies on the reversible,
noncovalent interaction of a ligand with its biological target, a targeted covalent inhibitor …

Cerium oxide nanoparticles (nanoceria) have shown promise as catalytic antioxidants in the
test tube, cell culture models and animal models of disease. However given the reactivity …

Drugs that function through covalent bond formation represent a considerable fraction of our
repository of effective medicines but safety concerns and the complexity of developing …

Drug-induced liver injury (DILI) presents unique challenges for consumers, clinicians, and
regulators. It is the most common cause of acute liver failure in the US. It is also one of the …

Nonclinical testing of human pharmaceuticals is conducted to assess the safety of
compounds to be studied in human clinical trials and for marketing of new drugs. Although …

Drug‐induced liver injury (DILI) is a major public health problem. Intrinsic (dose‐dependent)
DILI associated with acetaminophen overdose is the number one cause of acute liver failure …

Drug-induced liver injury is an important clinical problem and a challenge for drug
development. Whereas progress in understanding rare and unpredictable (idiosyncratic) …

Idiosyncratic drug-induced liver injury (IDILI) remains a significant problem for patients and
drug development. The idiosyncratic nature of IDILI makes mechanistic studies difficult, and …

Proteolysis-targeting chimeras (PROTACs) and targeted covalent inhibitors (TCIs) are
currently two exciting strategies in the fields of chemical biology and drug discovery …

Drug-induced liver injury (DILI) has become a major topic in the field of Hepatology and
Gastroenterology. DILI can be clinically divided into three phenotypes: hepatocytic …